Abdullah Mubarak, MD
Transplant Hepatology · Tyler, TXNPI 1336109925
Payments from drug & device makers
Across 1,500 payments — averaging $2817.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$1.1M
- Intercept Pharmaceuticals, Inc.$740K
- AbbVie$538K
- Madrigal Pharmaceuticals$409K
- Eli Lilly$335K
- Novartis$291K
- plus $824K from 23 others
Across 9 payments — averaging $4225.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$33K
- Eli Lilly$5K
What the payments were for
- Consulting fees$13,9904%
- Speaking & faculty fees$308,69585%
- Travel & lodging$24,3507%
- Food & beverage$14,8844%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 350 | $1,088,658 |
| Intercept Pharmaceuticals, Inc. | 128 | $740,237 |
| AbbVie(2 entities) | 203 | $538,119 |
| Madrigal Pharmaceuticals | 97 | $409,241 |
| Eli Lilly | 25 | $335,302 |
| Novartis | 9 | $290,919 |
| E.r. Squibb & Sons, L.L.C. | 8 | $245,256 |
| Gilead | 281 | $193,221 |
| Intercept Pharma Europe Ltd. | 5 | $139,634 |
| Regeneron | 209 | $120,422 |
| Ipsen Biopharmaceuticals, Inc | 62 | $76,374 |
| Ipsen Pharma SAS | 18 | $20,148 |
| Ipsen Bioscience Inc. | 29 | $13,888 |
| Dova Pharmaceuticals | 6 | $8,398 |
| Echosens North America, Inc. | 3 | $5,120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $774 |
| Perspectum Diagnostics Ltd | 4 | $187 |
| Kerecis Limited | 2 | $187 |
| Nevro Corp. | 1 | $86 |
| Novo Nordisk | 5 | $85 |
| Intra-sana Laboratories | 3 | $60 |
| Mirum Pharmaceuticals, Inc. | 3 | $55 |
| Sanofi | 1 | $36 |
| Lockedbrands | 1 | $30 |
| VBI Vaccine (delaware) Inc. | 1 | $29 |
| Eisai Inc. | 2 | $27 |
| Alcresta Therapeutics, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| QOL Medical, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$89,869
- Mavyret$86,422
- IQIRVO$66,341
- REZDIFFRA$48,138
- Livdelzi$20,959
- FibroScan$5,106
- Vemlidy$5,085
- Kerecis SurgiClose$707
- Kerecis GraftGuide$177
- XIFAXAN$110
How this compares
$4,226,558 in reported general payments places this provider in the 95th percentile of 28 transplant hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 184 | $605,793 |
| EpclusaSofosbuvir/Velpatasvir | 17 | $418,402 |
| VoseviSofosbuvir/Velpatas/Voxilaprev | 12 | $298,882 |
| OcalivaObeticholic Acid | 20 | $208,908 |
| IqirvoElafibranor | 14 | $188,596 |
| RezdiffraResmetirom | 32 | $128,807 |
| VemlidyTenofovir Alafenamide | 83 | $121,018 |
| Ursodiol | 280 | $31,083 |
| Mycophenolate Mofetil | 111 | $7,078 |
| Entecavir | 19 | $2,215 |
| Lactulose | 64 | $1,887 |
| Tacrolimus | 23 | $1,647 |
| Spironolactone | 112 | $1,022 |
| ConstuloseLactulose | 27 | $716 |
| Furosemide | 190 | $698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $774 | $605,793184 claims |
| GileadEpclusa, Vemlidy | $193,221 | $539,420100 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $740,237 | $208,90820 claims |
| Ipsen Biopharmaceuticals, IncIqirvo | $76,374 | $188,59614 claims |
| Madrigal PharmaceuticalsRezdiffra | $409,241 | $128,80732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 transplant hepatology providers in Texas.
Other transplant hepatology in Tyler
- Madhavi RudrarajuSan Antonio$8M
- Mangesh PagadalaDallas$1.9M
- David VictorHouston$1.3M
- Prasun JalalHouston$941K
- Carmen LandaverdeSan Antonio$757K
- Fernando MembrenoMcAllen$736K
- Stevan GonzalezFort Worth$515K
- Ruben Hernaez RodriguezHouston$251K
- Hector NazarioDallas$227K
- Saira KhaderiHouston$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.